Use of lipid conjugates in cystic fibrosis and applications thereof
OwnerSaul Yedgar, Alice Princeinventors
Life of this patent
Estimating the term…
Abstract
This invention provides for the use of compounds represented by the structure of the general formula (A): wherein L is a lipid or a phospholipid, Z is either nothing, ethanolamine, serine, inositol, choline, or glycerol, Y is either nothing or a spacer group ranging in length from 2 to 30 atoms, X is a physiologically acceptable monomer, dimer, oligomer, or polymer, wherein X is a glycosaminoglycan; and n is a number from 1 to 1000, wherein any bond between L, Z, Y and X is either an amide or an esteric bond in treating a subject suffering from cystic fibrosis, reducing or delaying the mortality of a subject suffering from cystic fibrosis or ameliorating symptoms associated with cystic fibrosis.
Claims35
A method for treating a subject suffering from cystic fibrosis, reducing or delaying the mortality of a subject suffering from cystic fibrosis or ameliorating symptoms associated with cystic fibrosis, the method comprising the step of administering a compound represented by the structure of the general formula (A):
- wherein
- L is a lipid or a phospholipid;
- Z is either nothing, ethanolamine, serine, inositol, choline, or glycerol;
- Y is either nothing or a spacer group ranging in length from 2 to 30 atoms;
- X is a physiologically acceptable monomer, dimer, oligomer, or polymer, wherein X is a glycosaminoglycan;
- and
- n is a number from 1 to 1000;
- wherein any bond between L, Z, Y and X is either an amide or an esteric bond to a subject afflicted with or suffering from symptoms of cystic fibrosis.
A method for decreasing expression of proinflammatory chemokines, cytokines, or a combination thereof comprising the step of administering a compound represented by the structure of the general formula (A):
- wherein
- L is a lipid or a phospholipid;
- Z is either nothing, ethanolamine, serine, inositol, choline, or glycerol;
- Y is either nothing or a spacer group ranging in length from 2 to 30 atoms;
- X is a physiologically acceptable monomer, dimer, oligomer, or polymer, wherein X is a glycosaminoglycan;
- and
- n is a number from 1 to 1000;
- wherein any bond between L, Z, Y and X is either an amide or an esteric bond to a subject with high levels of proinflammatory chemokines, cytokines, or a combination thereof.
A method of activating NF-κB, IL-6, IL-8, or a combination thereof in human airway epithelial cell lines comprising the step of administering to a subject a compound represented by the structure of the general formula (A):
- wherein
- L is a lipid or a phospholipid;
- Z is either nothing, ethanolamine, serine, inositol, choline, or glycerol;
- Y is either nothing or a spacer group ranging in length from 2 to 30 atoms;
- X is a physiologically acceptable monomer, dimer, oligomer, or polymer, wherein X is a glycosaminoglycan;
- and
- n is a number from 1 to 1000;
- wherein any bond between L, Z, Y and X is either an amide or an esteric bond.
Dependencies are inferred from the claim text.